Healthcare Industry News: bivalirudin
News Release - February 4, 2016
Eagle Pharmaceuticals Announces Appointment of Michael Moran as U.S. Head of SalesWOODCLIFF LAKE, N.J.--(Healthcare Sales & Marketing Network)--Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (EGRX) today announced that it has appointed Michael Moran, a seasoned sales executive in the pharmaceuticals industry, to the role of U.S. Head of Sales, effective immediately.
“Mike is an exceptional sales leader with a lengthy record of success in this industry, and we are very pleased to have him aboard,” said Scott Tarriff, President and Chief Executive Officer. “His extensive experience and innovative selling strategies will make him a valuable asset to Eagle as we continue to develop our sales capabilities, strengthening our market position as a fully commercial specialty company with a broad and growing portfolio. In particular, we expect to leverage his expertise to coordinate our co-promotional activities with Spectrum Pharmaceuticals, as we finalize building our 20 person internal sales force. Eagle will have about 50 people selling our products and Mike will be coordinating this activity on a national scale. His background makes him uniquely qualified to sell our in-market and forthcoming products, including Ryanodex, bivalirudin, Docetaxel, and Bendeka, among others. We look forward to benefiting from his experience.”
Michael Moran is an industry veteran with more than 15 years of experience in pharmaceutical sales. Prior to joining Eagle he spent seven years in various leadership roles at GlaxoSmithKline, including most recently the role of field vice president, where he oversaw more than 100 sales representatives and increased key customer reach by 45%. His additional accomplishments at GlaxoSmithKline include successfully coordinating several product launches across a global footprint, and negotiating the acquisition or co-promotion of additional products. He has received numerous awards in recognition of his outstanding project leadership and sales achievements.
“Eagle is an impressive company with exciting prospects, and I am thrilled to be joining the team at this key moment in its growth story,” said Mr. Moran. “Eagle’s high-quality portfolio of unique products, combined with its robust drug pipeline, have positioned it to realize numerous selling opportunities in areas with strong unmet demand. I am eager to collaborate with the Company’s partners and our own internal team to achieve meaningful growth in sales. It is a pleasure to be working with Eagle on products that represent such a compelling potential to improve, and even save, the lives of patients. I look forward to helping the Company deliver these treatments to the people and organizations that need them.”
Mr. Moran earned his B.S. in Business Management from the State University of New York at Empire, and completed the Transformational Leadership for Executives program at the University of Pennsylvania Wharton School of Business.
About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.
This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and other securities laws. Forward-looking statements are statements that are not historical facts. Words such as “believes,” “potential,” “will,” “may,” “intends,” “anticipate(s),” “plan,” “enables,” “potentially,” “entitles,” “realize,” “achieve,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: the effectiveness and/or success of Mr. Moran’s efforts on our behalf; the effectiveness and/or success of our co-promotional activities with Spectrum Pharmaceuticals; the success of our sales efforts with respect to our in-market products and forthcoming products; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; and other factors that are discussed in Eagle’s Annual Report on Form 10-K for the fiscal year ended September 30, 2014, and its other filings with the U.S. Securities and Exchange Commission. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond Eagle’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks include, but are not limited to: the effectiveness of Mr. Moran in his sales and promotional efforts; whether Spectrum Pharmaceuticals and Eagle will effectively coordinate their co-promotional efforts; whether the FDA will ultimately approve Eagle’s new product candidates; the commercial success of forthcoming products; and the other risks described in Eagle’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.
Source: Eagle Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.